Evofem Biosciences Announces Padagis Will Not Seek FDA Approval To Market A Generic Version Of Phexxi Until Evofem's Phexxi Patents Expire
-- Padagis Determined They Will Not Challenge the Phexxi Patents --
-- Evofem Has Phexxi Patent Protection Through 2033 --